Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
Titel:
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
Auteur:
Kundranda, M. Gracian, A.C. Zafar, S.F. Meiri, E. Bendell, J. Algül, H. Rivera, F. Ahn, E.R. Watkins, D. Pelzer, U. Charu, V. Zalutskaya, A. Kuesters, G. Pipas, J.M. Santillana, S. Askoxylakis, V. Ko, A.H.